Semax, Selank and DSIP are often grouped under labels such as “cognitive” or “sleep”, but that commercial grouping oversimplifies the literature. Each has a different sequence and experimental history.
Semax and Selank
Preclinical research explores neuromodulation, expression of selected factors and behavioural responses. Ac-Semax-NH₂ and Ac-Selank-NH₂ must not be confused with unmodified sequences.
DSIP and sleep literature
DSIP is a nonapeptide described in historical studies with heterogeneous results. The name does not establish a predictable effect or replace material characterisation.
Reading the evidence
Models, species, methods and endpoints differ. Claims about human memory, focus, anxiety or sleep cannot be inferred directly from preclinical experiments.
Conclusion
These materials are relevant as experimental tools only when identity and study design are clear. They are not presented for self-administration.
Method, sources and limitations
This material was written originally and reviewed to distinguish preclinical findings, human studies and commercial status. For legislation and authorisation, consult Directive 2001/83/EC, the EMA and relevant primary scientific literature.
For research use only (RUO). Not for use in humans. This article is not medical or legal advice and provides no instructions for use.